ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

entecavir

Also written as “Entecavir”, “Entecavir (ETV)” and “Entecavir + Tenofovir”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 6 companies.

Drug pageEntecavir: every studyMany companies study it; this page follows only the 32 they lead. All 104 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 29, 200632 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only240 open or runningphase 4since Aug 29, 2006May 4, 2002none ahead
Hoffmann-La Rocheits history only40 open or runningphase 4since Jan 30, 2008Jan 30, 2008none ahead
Ascentage Pharma Group Internationalits history only11 open or runningphase 2since Sep 24, 2020Sep 24, 2020none ahead
Aucta Pharmaceuticals10 open or runningphase 1since Jul 27, 2017Jul 27, 2017none ahead
Hanmi Pharmaceuticalits history only10 open or runningphase 4since Jul 26, 2015Jul 26, 2015none ahead
Sino Biopharmaceuticalits history only10 open or runningno phasesince Jan 22, 2019Jan 22, 2019none ahead

Also a collaborator on its studies: ICON Clinical Research and CPR Pharma Services Pty Ltd, Australia.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 27, 2017First study: phase 1 study in HBVFirst studyNCT03239353 · 40 enrolled · Australia

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA polymerase/reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

The one study Aucta Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03239353HBV · Australia1CompletedMay 29, 201840

How it is read

Names in the registry

  • “Entecavir”, 28 entries
  • “entecavir”, 4 entries
  • “Entecavir (ETV)”, 2 entries
  • “Entecavir + Tenofovir”, 2 entries
  • “P1101 + Nivolumab + Entecavir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.